- Home
- CRBP vs ARL Comparison
CRBP vs ARL Comparison
Compare CRBP & ARL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- ARL
- Stock Information
- Founded
- CRBP 2009
- ARL 1999
- Country
- CRBP United States
- ARL United States
- Employees
- CRBP N/A
- ARL N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- ARL Building operators
- Sector
- CRBP Health Care
- ARL Real Estate
- Exchange
- CRBP Nasdaq
- ARL Nasdaq
- Market Cap
- CRBP 210.8M
- ARL 245.7M
- IPO Year
- CRBP N/A
- ARL N/A
- Fundamental
- Price
- CRBP $11.23
- ARL $15.39
- Analyst Decision
- CRBP Strong Buy
- ARL
- Analyst Count
- CRBP 9
- ARL 0
- Target Price
- CRBP $48.38
- ARL N/A
- AVG Volume (30 Days)
- CRBP 546.2K
- ARL 1.9K
- Earning Date
- CRBP 11-12-2025
- ARL 11-06-2025
- Dividend Yield
- CRBP N/A
- ARL N/A
- EPS Growth
- CRBP N/A
- ARL N/A
- EPS
- CRBP N/A
- ARL 0.36
- Revenue
- CRBP N/A
- ARL $49,060,000.00
- Revenue This Year
- CRBP N/A
- ARL N/A
- Revenue Next Year
- CRBP $220.00
- ARL N/A
- P/E Ratio
- CRBP N/A
- ARL $43.16
- Revenue Growth
- CRBP N/A
- ARL N/A
- 52 Week Low
- CRBP $4.64
- ARL $9.43
- 52 Week High
- CRBP $20.56
- ARL $18.00
- Technical
- Relative Strength Index (RSI)
- CRBP 38.90
- ARL 47.12
- Support Level
- CRBP $10.88
- ARL $14.95
- Resistance Level
- CRBP $12.43
- ARL $15.52
- Average True Range (ATR)
- CRBP 0.76
- ARL 0.33
- MACD
- CRBP 0.05
- ARL -0.10
- Stochastic Oscillator
- CRBP 51.59
- ARL 21.42
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About ARL American Realty Investors Inc.
American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments; the acquisition, development, ownership and management of multifamily properties (Residential); and the acquisition, development, ownership, and management of commercial properties (Commercial), which predominantly comprise office properties. Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.